* Aradigm believes the NCFBE indication for Linhaliq exceed $500MM of sales by 2021. Ladenburhg analysts project $1B sales by 2022, Nektar projected $750 milion for their NCFBE product with Bayer
* US Orphan Drug Designation with no existing approved therapies
* QIDP Designation and Fast Track received FDA priority review accompanies QIDP designation
* Strong IP protection to 2031 8 patents issued in US; 41 issued patents in 37 countries outside the US
* Important objectives achieved in Phase 3 Prevention and reduction in frequency of pulmonary exacerbations High persistent drug contrentrations in sputum, low in blood Sustained powerful antipseudomonal activity even for patients with resistant isolates Good safety and tolerability
* Commercial Launch in US expected in Q2'2018 EU approval expected Q4'18/Q1'19
* Sole competitor: Bayer's twice dily, dry powder inhaled ciprofloxacin
* Linhaliq is administered once daily: Active in biofilms, uptake by macrophages
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.